

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Shendelman Shoshana</u> (Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 (Street) NEW YORK NY 10017 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc. [APLT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President and CEO
	3. Date of Earliest Transaction (Month/Day/Year) 08/02/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$3.33	08/02/2022		D ⁽¹⁾			234,616	(2)	01/25/2032	Common Stock	234,616	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D ⁽¹⁾		234,616		(2)	01/25/2032	Common Stock	234,616	(1)	234,616	D	
Employee Stock Option (Right to Buy)	\$23.15	08/02/2022		D ⁽¹⁾		101,670		(3)	12/10/2030	Common Stock	101,670	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D ⁽¹⁾		101,670		(3)	12/10/2030	Common Stock	101,670	(1)	101,670	D	
Employee Stock Option (Right to Buy)	\$22.2	08/02/2022		D ⁽¹⁾		134,979		(4)	12/16/2029	Common Stock	134,979	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D ⁽¹⁾		134,979		(4)	12/16/2029	Common Stock	134,979	(1)	134,979	D	
Employee Stock Option (Right to Buy)	\$22.2	08/02/2022		D ⁽¹⁾		23,317		(5)	12/16/2019	Common Stock	23,317	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D ⁽¹⁾		23,317		(5)	12/16/2019	Common Stock	23,317	(1)	23,317	D	
Employee Stock Option (Right to Buy)	\$10	08/02/2022		D ⁽¹⁾		607,484		(5)	05/12/2029	Common Stock	607,484	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D ⁽¹⁾		607,484		(5)	05/12/2029	Common Stock	607,484	(1)	607,484	D	

Explanation of Responses:

- The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.
- These Options are fully vested.

3. Reflects an initial grant of 256,850 Options granted on December 10, 2020 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 10, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

4. Reflects an initial grant of 209,000 Options granted on December 16, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 16, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

5. Reflects an initial grant of 767,349 Options granted on May 13, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on May 13, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

/s/ Shoshana Shendelman

08/04/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.